Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 12, 2014, Pages 4656-4663

  Roussel, Ronan ^a,b,d   Fezeu, Léopold ^a   Marre, Michel ^a,b,d   Velho, Gilberto ^a   Fumeron, Frédéric ^a,d   Jungers, Paul ^e   Lantieri, Olivier ^f   Balkau, Beverley ^g,h   Bouby, Nadine ^a,c   Bankir, Lise ^a,c   Bichet, Daniel G ⁱ  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f LA Riche   (France)

^g CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^h UNIVERSITÉ PARIS SACLAY   (France)

ⁱ HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COPEPTIN; VASOPRESSIN; WATER; GLYCOPEPTIDE; VASOPRESSIN DERIVATIVE;

ADULT; ARTICLE; BEVERAGE; CHRONIC KIDNEY DISEASE; COMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; COPEPTIN BLOOD LEVEL; FEMALE; FLUID INTAKE; GLOMERULUS FILTRATION RATE; HORMONE BLOOD LEVEL; HUMAN; KIDNEY CLEARANCE; KIDNEY CONCENTRATING CAPACITY; MAJOR CLINICAL STUDY; MALE; URINE OSMOLALITY; VASOPRESSIN BLOOD LEVEL; AGED; BLOOD; CHRONIC KIDNEY FAILURE; DRINKING; MIDDLE AGED; OSMOLARITY;

ADULT; AGED; DRINKING; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOPEPTIDES; HUMANS; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; RENAL INSUFFICIENCY, CHRONIC; VASOPRESSINS;

EID: 84916620185     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2295     Document Type: Article

References (31)

1. Robertson GL. Thirst and vasopressin function in normal and disordered states of water balance. J Lab Clin Med. 1983;101:351-371.
2. Bankir L, Bouby N, Ritz E. Vasopressin: A novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol. 2013;9:223-239.
3. Koshimizu TA, Nakamura K, Egashira N, Hiroyama M,Nonoguchi H, Tanoue A. Vasopressin V1a and V1b receptors: From molecules to physiological systems. Physiol Rev. 2012;92:1813-1864.
4. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52:112-119.
5. Morgenthaler NG, Struck J, Jochberger S, Dunser MW. Copeptin: Clinical use of a new biomarker. Trends Endocrinol Metab. 2008;19:43-49.
6. Boertien WE, Meijer E, Li J, et al. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: Results from the CRISP cohort. Am J Kidney Dis. 2013;61: 420-429.
7. Boertien WE, Riphagen IJ, Drion I, et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). Diabetologia. 2013;56:1680-1688.
8. Fenske W, Quinkler M, Lorenz D, et al. Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome-revisiting the direct and indirect water deprivation tests. J Clin Endocrinol Metab. 2011;96:1506-1515.
9. Morgenthaler NG, Müller B, Struck J, Bergmann A, Redl H, Christ-Crain M. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock. 2007;28:219-226.
10. Velho G, Bouby N, Hadjadj S, et al. Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care. 2013;36:3639-3645.
11. Giannopoulos G, Deftereos S, Panagopoulou V, et al. Copeptin as a biomarker in cardiac disease. Curr Top Med Chem. 2013;13:231-240.
12. Yalta K, Yalta T, Sivri N, Yetkin E. Copeptin and cardiovascular disease: A review of a novel neurohormone. Int J Cardiol. 2013;167:1750-1759.
13. Nickel CH, Bingisser R, Morgenthaler NG. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Med. 2012;10:7.
14. Maisel A, Mueller C, Neath SX, et al. Copeptin helps in the early detection of patients with acute myocardial infarction: Primary results of the CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction). J Am Coll Cardiol. 2013;62:150-160.
15. Stoiser B, Mörtl D, Hülsmann M, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest. 2006;36:771-778.
16. Enhörning S, Wang TJ, Nilsson PM, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation. 2010;121:2102-2108.
17. Boertien WE, Meijer E, Zittema D, et al. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2012;27:4131-4137.
18. Jochberger S, Dörler J, Luckner G, et al. The vasopressin and copeptin response to infection, severe sepsis, and septic shock. Crit Care Med. 2009;37:476-482.
19. Balanescu S, Kopp P, Gaskill MB, Morgenthaler NG, Schindler C, Rutishauser J. Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar States. J Clin Endocrinol Metab. 2011;96:1046-1052.
20. Simmler LD, Hysek CM, Liechti ME. Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects. J Clin Endocrinol Metab. 2011;96:2844-2850.
21. Balkau B, Lange C, Fezeu L, et al. Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes care. 2008;31:2056-2061.
22. 2: The role of gamma-glutamyltransferase. Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetologia. 2010;53:247-253.
23. Konrat C, Mennen LI, Cacès E, et al. Alcohol intake and fasting insulin in French men and women. The D.E.S.I.R. Study. Diabetes Metab. 2002;28:116-123.
24. Roussel R, Fezeu L, Bouby N, et al. Low water intake and risk for new-onset hyperglycemia. Diabetes Care. 2011;34:2551-2554.
25. Bankir L, Perucca J, Weinberger MH. Ethnic differences in urine concentration: Possible relationship to blood pressure. Clin J Am Soc Nephrol. 2007;2:304-312.
26. Perucca J, Bouby N, Valeix P, Bankir L. Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease. Am J Physiol Regul Integr Comp Physiol. 2007;292:R700-R705.
27. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
28. Fenske W, Störk S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab. 2009;94:123-129.
29. Bichet DG, Arthus MF, Barjon JN, Lonergan M, Kortas C. Human platelet fraction arginine-vasopressin. Potential physiological role. J Clin Invest. 1987;79:881-887.
30. Bichet DG, Kortas C, Mettauer B, et al. Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. Kidney Int. 1986;29:1188-1196.
31. Westermann I, Dunser MW, Haas T, et al. Endogenous vasopressin and copeptin response in multiple trauma patients. Shock. 2007;28:644-649.